INCB086550

DRUG4 trials

Sponsors

Incyte Corporation, Incyte Biosciences Japan GK

Conditions

Healthy VolunteersHepatocellular CarcinomaMelanomaNon Small Cell Lung CancerRenal Cell CarcinomaSolid TumorsUrothelial Cancer

Phase 1

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

CompletedNCT03762447

Incyte CorporationSolid Tumors

Start: 2018-12-10End: 2023-11-17Updated: 2025-08-11

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

TerminatedNCT04674748

Incyte Biosciences Japan GKSolid Tumors

Start: 2021-02-03End: 2022-05-13Updated: 2025-09-24

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550

CompletedNCT05101369

Incyte CorporationHealthy Volunteers

Start: 2022-01-21End: 2022-03-25Updated: 2025-08-21

Phase 2

Study of INCB086550 in Select Solid Tumors

TerminatedNCT04629339

Incyte CorporationHepatocellular Carcinoma, Melanoma, Non Small Cell Lung Cancer +2

Start: 2021-09-02End: 2024-03-26Updated: 2025-03-13

Related Papers

529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-0111 citations